Zymeworks Common Stock Stock Alpha and Beta Analysis
| ZYME Stock | USD 13.10 0.04 0.31% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Zymeworks Common Stock. It also helps investors analyze the systematic and unsystematic risks associated with investing in Zymeworks Common over a specified time horizon. Remember, high Zymeworks Common's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Zymeworks Common's market risk premium analysis include:
Beta 0.99 | Alpha 0.089 | Risk 3.09 | Sharpe Ratio 0.0519 | Expected Return 0.16 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Zymeworks |
Zymeworks Common Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Zymeworks Common market risk premium is the additional return an investor will receive from holding Zymeworks Common long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Zymeworks Common. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Zymeworks Common's performance over market.| α | 0.09 | β | 0.99 |
Zymeworks Common expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Zymeworks Common's Buy-and-hold return. Our buy-and-hold chart shows how Zymeworks Common performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Zymeworks Common Market Price Analysis
Market price analysis indicators help investors to evaluate how Zymeworks Common stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zymeworks Common shares will generate the highest return on investment. By understating and applying Zymeworks Common stock market price indicators, traders can identify Zymeworks Common position entry and exit signals to maximize returns.
Zymeworks Common Return and Market Media
The median price of Zymeworks Common for the period between Thu, Sep 12, 2024 and Wed, Dec 11, 2024 is 13.28 with a coefficient of variation of 9.98. The daily time series for the period is distributed with a sample standard deviation of 1.36, arithmetic mean of 13.66, and mean deviation of 1.06. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Epigenetics Market to Witness 14.8 percent CAGR by 2031 SkyQuest Technology | 09/24/2024 |
2 | Zymeworks Inc. Reports Q3 Loss, Lags Revenue Estimates | 10/31/2024 |
3 | Zymeworks Inc. Analysts Are Reducing Their Forecasts For Next Year | 11/01/2024 |
4 | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor- Expressing Advanced Solid Tumors | 11/05/2024 |
5 | Zymeworks Upgraded at Leerink Partnrs | 11/08/2024 |
6 | CAR T-Cell Therapy Market to Surpass Valuation of USD 106.06 Billion by 2031 SkyQuest Technology | 11/18/2024 |
7 | Acquisition by Kenneth Galbraith of 215000 shares of Zymeworks Common at 8.0 subject to Rule 16b-3 | 11/20/2024 |
8 | FDA Grants U.S. Approval of Ziihera for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive Biliary Tract Cancer | 11/21/2024 |
9 | Zymeworks Stock Price Down 7.2 percent Time to Sell | 12/09/2024 |
About Zymeworks Common Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Zymeworks or other stocks. Alpha measures the amount that position in Zymeworks Common Stock has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 20.9 | 18.01 | 16.18 | 11.22 | Receivables Turnover | 1.71 | 12.35 | 3.9 | 3.71 |
Zymeworks Common Upcoming Company Events
As portrayed in its financial statements, the presentation of Zymeworks Common's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Zymeworks Common's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Zymeworks Common. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Zymeworks Common
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Zymeworks Common Backtesting, Zymeworks Common Valuation, Zymeworks Common Correlation, Zymeworks Common Hype Analysis, Zymeworks Common Volatility, Zymeworks Common History and analyze Zymeworks Common Performance. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Zymeworks Common technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.